venBio
View More Recent Stories
-
venBio Closes $315 Million Life Sciences Venture Capital Fund
-
Form SC 13G Nabriva Therapeutics AG Filed by: venBio Global Strategic Fund II L.P.
-
Checkmate Pharmaceuticals Appoints David Mauro, M.D., Ph.D., as Chief Medical Officer and Announces Dosing of First Patient in Immuno-Oncology Phase 1b Trial with CMP-001, a TLR9 Agonist
-
Heart Metabolics Announces Multiple Senior Appointments To Management Team
-
Form 13F-HR venBio Select Advisor For: Dec 31
-
Form SC 13G PERNIX THERAPEUTICS HOLD Filed by: venBio Select Advisor LLC
-
Form SC 13G Mirati Therapeutics, Filed by: venBio Select Advisor LLC
-
Form SC 13G Lion Biotechnologies, Filed by: venBio Select Advisor LLC
-
Apellis Completes $47 Million Series D Financing
-
PlacementTracker Publishes 2015 PIPE Market League Tables
-
Form 13F-HR venBio Select Advisor For: Sep 30
-
EY and SolomonEdwards honor the 2015 Venture Capital Award of Excellence winners
-
PlacementTracker Publishes Third Quarter 2015 PIPE Market League Tables
-
Oncobiologics Secures Financing from Sabby Management, LLC, to Advance BioSymphony™ Platform and Monoclonal Antibody Biosimilars Pipeline
-
Corvus Pharmaceuticals Completes $75 Million Series B Financing
-
venBio's New Biotech Bet is One to Watch

